Moratilla-Rivera Ignacio, Pérez-Jiménez Jara, Ramos Sonia, Portillo María Puy, Martín María Ángeles, Mateos Raquel
Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN), Consejo Superior de Investigaciones Científicas (CSIC), C/Jose Antonio Novais 6, 28040, Madrid, Spain; Faculty of Biological Sciences, Universidad Complutense de Madrid, Ciudad Universitaria s/n, 28040, Madrid, Spain.
Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN), Consejo Superior de Investigaciones Científicas (CSIC), C/Jose Antonio Novais 6, 28040, Madrid, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain.
Clin Nutr. 2025 Sep;52:17-26. doi: 10.1016/j.clnu.2025.07.006. Epub 2025 Jul 12.
BACKGROUND & AIM: Hydroxytyrosol (HT), an olive-derived phenolic compound, possesses well-known antioxidant and anti-inflammatory properties. While its benefits in healthy individuals and as part of extra virgin olive oil are well studied, its preventive role as a dietary supplement in at-risk populations remains less explored. This study investigates the potential of HT supplementation in preventing aging-related diseases in overweight individuals with prediabetes.
A randomized, double-blind, placebo-controlled trial was conducted in adults with overweight and prediabetes (40-70 years). For 16 weeks, volunteers consumed either 15 mg of HT or a placebo daily. The primary outcome were oxidized LDL (oxLDL) levels, while secondary outcomes included biochemical and metabolic parameters, oxidative stress and inflammation biomarkers, and lifestyle assessments. Compliance was verified through urinary HT-3'-sulphate levels.
A total of 52 participants were recruited and randomized, with 49 completing the study. They were then allocated to either the HT-treated group (n = 24) or the placebo group (n = 25). Compliance was confirmed, as the HT-supplemented group showed increased urinary HT-3'-sulphate levels, whereas the placebo group exhibited a significant decrease (p = 0.039). Compared with placebo, HT supplementation significantly reduced oxLDL levels (p = 0.045), protein carbonyls (p = 0.031), and 8-OHdG (p < 0.01). Additionally, it prevented a decline in total antioxidant status (p < 0.01) and GPx activity (p < 0.01). An anti-inflammatory effect was also observed, with reduced IL-6 levels (p = 0.05). No significant changes were found in lipid profile, anthropometric parameters, or lifestyle factors such as sleep, mental well-being, or physical capacity. No adverse events were observed throughout the intervention.
Chronic supplementation with 15 mg/day of HT for 16 weeks significantly improved antioxidant and anti-inflammatory status in individuals with overweight and prediabetes, suggesting a potential preventive role against aging-related diseases.
NCT06295913 (https://clinicaltrials.gov/study/NCT06295913?intr=Hydroxytyrosol&page=2&rank=1).
羟基酪醇（HT）是一种源自橄榄的酚类化合物，具有众所周知的抗氧化和抗炎特性。虽然其在健康个体以及作为特级初榨橄榄油一部分的益处已得到充分研究，但其作为膳食补充剂在高危人群中的预防作用仍有待进一步探索。本研究调查了补充HT对预防超重且患有糖尿病前期的个体中与衰老相关疾病的潜力。
对超重且患有糖尿病前期的成年人（40 - 70岁）进行了一项随机、双盲、安慰剂对照试验。在16周内，志愿者每天服用15毫克HT或安慰剂。主要结局指标是氧化型低密度脂蛋白（oxLDL）水平，次要结局指标包括生化和代谢参数、氧化应激和炎症生物标志物以及生活方式评估。通过尿中HT - 3'-硫酸盐水平验证依从性。
共招募了52名参与者并进行随机分组，49人完成了研究。然后将他们分为HT治疗组（n = 24）或安慰剂组（n = 25）。由于补充HT组尿中HT - 3'-硫酸盐水平升高，而安慰剂组显著降低（p = 0.039），因此证实了依从性。与安慰剂相比，补充HT显著降低了oxLDL水平（p = 0.045）、蛋白质羰基水平（p = 0.031）和8 - 羟基脱氧鸟苷（8 - OHdG）水平（p < 0.01）。此外，它还防止了总抗氧化状态（p < 0.01）和谷胱甘肽过氧化物酶（GPx）活性的下降（p < 0.01）。还观察到了抗炎作用，白细胞介素 - 6（IL - 6）水平降低（p = 0.05）。在血脂谱、人体测量参数或生活方式因素如睡眠、心理健康或身体能力方面未发现显著变化。在整个干预过程中未观察到不良事件。
每天15毫克HT连续补充16周可显著改善超重且患有糖尿病前期个体的抗氧化和抗炎状态，表明其对与衰老相关疾病具有潜在的预防作用。
NCT06295913（https://clinicaltrials.gov/study/NCT06295913?intr=Hydroxytyrosol&page=2&rank=1）。
